share_log

中国生物制药(01177):KRAS G12C抑制剂“GARSORASIB(D-1553片)”II期临床研究数据将在2024 AACR公布

China Biopharmaceutical (01177): Phase II clinical study data for the KRAS G12C inhibitor “GARSORASIB (D-1553 tablets)” will be announced at 2024 AACR

Zhitong Finance ·  Mar 13 04:37

Zhitong Finance App News, China Biopharmaceutical (01177) announced that the KRAS G12C inhibitor “Garsorasib (D-1553 tablets)” jointly developed by the group will announce the latest results of the Phase II clinical study (NCT05383898) at the 2024 American Cancer Association Annual Meeting (AACR) to treat patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment